

Special Issue

Innovations in Endocrine Cancer—Technology, Techniques and Therapy (Second Edition)

Message from the Guest Editor

This Special Issue is the second edition of a previous Special Issue entitled “Innovations in Endocrine Cancer—Technology, Techniques and Therapy”

(https://www.mdpi.com/journal/cancers/special_issues/FTTMW38K70). As , I am pleased to introduce this Special Issue of *Cancers* entitled “Innovations in Endocrine Cancer—Technology, Techniques and Therapy (2nd Edition)”. The past decade has witnessed significant innovation in the field of endocrinology, with novel surgical approaches, technologies and medications changing the way we practice. We invite authors to contribute research articles and reviews that are relevant to the field of endocrinology, including discussions of topics such as the thyroid gland, the parathyroid glands, the adrenal gland, and melanomas. We particularly welcome articles that discuss imaging studies (e.g., ultrasound, CT, MRI, and PET/CT), novel approaches (e.g., minimally invasive techniques and remote-access approaches), and the putative genetic markers of disease.

Guest Editor

Prof. Dr. Emad H. Kandil

Division of Endocrine and Oncologic Surgery, Department of Surgery, Tulane University School of Medicine, New Orleans, LA 70112, USA

Deadline for manuscript submissions

closed (30 April 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/si/226426](https://www.mdpi.com/si/226426)

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://www.mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)